Modeling and simulation will be a key component for shift to non-animal methodologies Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy ...
The National Institutes of Health (NIH) is following in the FDA’s footsteps—away from animal testing. The NIH plans to establish a new office meant to develop nonanimal methods for biomedical research ...
The National Institutes of Health announced on Monday that the biomedical agency will no longer award funding to new grant proposals solely relying upon animal testing and will require that applicants ...
AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to reduce or replace animal testing in favor of novel methods, such as ...
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Pharma has long taken small steps toward phasing out animal ...
The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal antibodies and some other drug candidates. Animal testing will be "reduced, ...
The National Institutes of Health announced on Monday that the biomedical agency will no longer put out new funding opportunities solely relying upon animal testing and will require that applicants ...
The pharmaceutical and medical device industries stand at an inflection point. After decades of reliance on traditional randomized controlled trials (RCTs), computational modeling and simulation (CM&S ...
The U.S. Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback